Agios Pharmaceuticals Inc. (NASDAQ:AGIO) shares traded higher over the last trading session, gaining 1.65% on 06/17/21. The shares fell to a low of $58.45 before closing at $59.75. Intraday shares traded counted 0.49 million, which was 23.08% higher than its 30-day average trading volume of 634.75K. AGIO’s previous close was $58.78 while the outstanding shares total 69.54M. The firm has a beta of 1.63. The stock’s Relative Strength Index (RSI) is 62.42, with weekly volatility at 2.89% and ATR at 1.75. The AGIO stock’s 52-week price range has touched low of $32.47 and a $60.71 high.
Investors have identified the Biotechnology company Agios Pharmaceuticals Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $3.79 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Agios Pharmaceuticals Inc. (AGIO) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 2.36 billion total, with 96.5 million as their total liabilities.
AGIO were able to record -121.76 million as free cash flow during the 08/05/2021 quarter of the year, this saw their quarterly net cash flow reduce by 1.76 billion. In cash movements, the company had a total of -120.75 million as operating cash flow.
Having a look at the company’s valuation, the company is expected to record -6.58 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on AGIO sounds very interesting.
Is the stock of AGIO attractive?
In related news, Chief Medical Officer, Bowden Christopher sold 20,853 shares of the company’s stock in a transaction that recorded on Jun 10. The sale was performed at an average price of 60.06, for a total value of 1,252,437. As the sale deal closes, the Chief Medical Officer, Bowden Christopher now sold 7,149 shares of the company’s stock, valued at 430,117. Also, Chief Medical Officer, Bowden Christopher sold 6,675 shares of the company’s stock in a deal that was recorded on Jun 08. The shares were price at an average price of 60.07 per share, with a total market value of 400,939. Following this completion of acquisition, the Chief Medical Officer, Bowden Christopher now holds 4,268 shares of the company’s stock, valued at 256,232. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.40%.
8 out of 12 analysts covering the stock have rated it a Buy, while 4 have maintained a Hold recommendation on Agios Pharmaceuticals Inc.. 0 analysts has assigned a Sell rating on the AGIO stock. The 12-month mean consensus price target for the company’s shares has been set at $63.50.